Ochoa-Azze RF

Language: Spanish
References: 11
Page: 44-46
PDF size: 232.91 Kb.

Text Extraction

Meningococcal vaccines against serogroups A, C, Y, W₁₃₅, X are based on capsular polysaccharides. This structure confer resistance to host complement-mediated attack mechanisms. The capsular polysaccharide of Neisseria meningitidis serogroup B has not been used. It is poorly immunogenic, because it is similar to polysialic acid expressed on host neural cell adhesion molecule. For that reason, other immunogens have been evaluated. These include vaccines based on outer membrane vesicles (OMV).
The serum bactericidal assay (SBA) is the “gold standard” to evaluate the immunogenicity of meningococcal vaccines. The immune correlate of protection against serogroup B has been defined as bactericidal titers ≥1:4; and ≥1:8 for serogroup C, especially when human complement is used.

REFERENCES

1. Bai X, Borrow R, Bukovski S, Caugant DA, Culic D, Delic S, et al. Prevention and control of meningococcal disease: Updates from the Global Meningococcal Initiative in Eastern Europe. J Infect 2019;79:528-41.

2. Sierra-González VG. Cuban Meningococcal Vaccine VA-MENGOC-BC:30 Years of Use and Future Potential. MEDICC Rev 2019;21(4):19-27.

3. Ochoa-Azze RF, García-Imia L, Vérez-Bencomo V. Effectiveness of a Serogroup B and C Meningococcal Vaccine Developed in Cuba. MEDICC Rev 2018;20(3):22-9.

4. McIntosh ED, Bröker M, Wassil J, Welsch JA, Borrow R Serum bactericidal antibody assays - The role of complement in infection and immunity. Vaccine 2015;33:4414-21.

5. Ochoa-Azze RF. Cross protection induced by VA-MENGOC-BC® vaccine. Hum Vaccin Immunother 2018;14(5):1064-8

6. Pérez O, Lastre M, Lapinet J, Bracho G, Díaz M, Zayas C, et al. Immune Response Induction and New Effector Mechanisms Possibly Involved in Protection Conferred by the Cuban Anti-Meningococcal BC Vaccine. Infect Immun 2001;69:4502-8.

7. Read RC, Dull P, Bai X, Nolan K, Findlow J, Bazar R, et al. A phase III observer-blind randomized, controlled study to evaluate the immune response and the correlation with nasopharyngeal carriage after immunization of university students with a quadrivalent meningococcal ACWY glycoconjugate or serogroup B meningococcal vaccine. Vaccine 2017;35:427-34.

8. Boccadifuoco G, Brunelli B, Mori E, Agnusdei M, Gianfaldoni C, Giuliani MM. Meningococcal Antigen Typing System (MATS): A Tool to Estimate Global Coverage for 4CMenB, a Multicomponent Meningococcal B Vaccine. Methods Mol Biol 2019;1969:205-15.

9. Donald RGK, Hawkins JC, Hao L, Liberator P, Jones TR, Harris SL, et al. Meningococcal serogroup B vaccines: Estimating breadth of coverage. Hum Vaccin Immunother 2017;13(2):1-11.

10. Morley S, Cole M, Ison C, Camaraza MA, Sotolongo F, Anwar N, et al. Immunogenicity of a serogroup B meningococcal vaccine against multiple Neisseria meningitidis strains in infants. Pediatr Infect Dis J. 2001;20:1054-61.

11. Sotolongo-Padrón F, Campa-Huergo C, Casanueva-Gil V, Fajardo-Díaz EM, MSc, Cuevas-Valdespino IE, González-Gotera N. Cuban Meningococcal BC Vaccine: Experiences & Contributions from 20 Years of Application. MEDICC Rev 2007;9(1):16-22.